← All Scienture Holdings, INC filings

Scienture Holdings, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SCNX
Scienture Holdings, INC
10-K/A: Scienture Holdings 10-K/A: Strategic Realignment Update
Scienture Holdings files an amended 2025 annual report to correct immaterial errors and provide required governance disclosures.
NASDAQ
SCNX
Scienture Holdings, INC
10-K: Scienture posts big loss, launches first drug
Scienture Holdings reported a $41.5M FY25 loss amid $26.3M impairments, launched FDA‑approved ARBLI and secured U.S. rights to 10mg naloxone nasal spray REZENOPY.
NASDAQ
SCNX
Scienture Holdings, INC
10-K: Scienture Holdings Reports FY24 Results, Highlights Scienture LLC Acquisition and Strategic Shift
Scienture Holdings, formerly TRxADE HEALTH, reports its FY24 results, emphasizing the acquisition of Scienture LLC and a strategic shift towards CNS and CVS disease treatments.
NASDAQ
SCNX
Scienture Holdings, INC
10-K/A: TRxADE HEALTH, INC. Files Amendment to 2023 Annual Report
TRxADE HEALTH, INC. has filed an amendment to its 2023 annual report on Form 10-K/A to include previously omitted information and updated certifications.
NASDAQ
SCNX
Scienture Holdings, INC
10-K: TRxADE HEALTH, INC. Reports Full Year 2023 Results Amidst Strategic Shifts
TRxADE HEALTH, INC. reports a net loss of $13.7 million for 2023, impacted by strategic divestitures and operational changes.